Benzinga's Microcap Movers for Wednesday June 13, 2012

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Shares of USEC

, the Bethesda, MD supplier of nuclear fuel and advanced technology solutions, rose 25.13% Wednesday on 10 times the average daily volume. USEC and the Department of Energy have signed agreements to move forward with a $350 million cooperative research, development and demonstration program to confirm the technical readiness of the American Centrifuge, the next-generation U.S. uranium enrichment technology. Benzinga reported heavy volume in the June 1 call last week with 2,042 contracts traded on June 6. USEC closed at $0.95 on Wednesday.

Shares of Media Sentiment (

), the San Francisco, CA online news media analysis research service, rose 50% Wednesday on 96 million shares traded. Sweetwater Resources announced on Tuesday its current share structure: Shares Outstanding 6,033,601,970 a/o June 6, 2012 -Float 1,078,526,970 a/o June 6, 2012 -Authorized 7,380,000,000 a/o June 6, 2012 The outstanding has been reduced by about 1.37 billion shares and the authorized has been reduced by 42.5 billion shares. Media Sentiment received the approval from the state of Wyoming to restate the Articles of Incorporation to reduce the number of authorized shares to 7,500,000,00 from 50,000,000,000. Media Sentiment closed at $0.0003 on Wednesday.

Shares of Advaxis (

), the Princeton, NJ biotechnology company, rose 15.56% Wednesday on 5.5 times the average daily volume. Advaxis announced Thursday the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer. “ADXS-PSA continues to demonstrate activity in models of prostate cancer, confirming our decision to move this construct into clinical development. The potential synergy of ADXS-PSA and radiotherapy observed in this study suggests that ADXS-PSA might be combined with other therapies that show efficacy in this type of tumor,” commented Dr. John Rothman, EVP of Science and Operations at Advaxis. Advaxis closed at $0.104 on Wednesday.